| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 647 | 2013 |
| Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer BJ Monk, TJ Herzog, SB Kaye, CN Krasner, JB Vermorken, FM Muggia, ... Journal of clinical oncology 28 (19), 3107-3114, 2010 | 499 | 2010 |
| European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer MHM Oonk, F Planchamp, P Baldwin, M Bidzinski, M Brännström, ... International Journal of Gynecologic Cancer 27 (4), 2017 | 211 | 2017 |
| Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—the MIMOSA study P Sabbatini, P Harter, G Scambia, J Sehouli, W Meier, P Wimberger, ... Journal of clinical oncology 31 (12), 1554, 2013 | 167 | 2013 |
| Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and … DS Alberts, C Marth, RD Alvarez, G Johnson, M Bidzinski, DR Kardatzke, ... Gynecologic oncology 109 (2), 174-181, 2008 | 145 | 2008 |
| Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent … N Colombo, E Kutarska, M Dimopoulos, DS Bae, I Rzepka-Gorska, ... J Clin Oncol 30 (31), 3841-3847, 2012 | 127 | 2012 |
| Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive … JM Del Campo, A Roszak, M Bidzinski, TE Ciuleanu, T Hogberg, ... Annals of oncology 20 (11), 1794-1802, 2009 | 77 | 2009 |
| Early cervical cancer managed by laparoscopy and conventional surgery: comparison of treatment results P Sobiczewski, M Bidzinski, P Derlatka, G Panek, A Danska-Bidzinska, ... International Journal of Gynecologic Cancer 19 (8), 2009 | 71 | 2009 |
| The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma J Radziszewski, M Kowalewska, T Jedrzejczak, I Kozlowicz-Gudzinska, ... Gynecologic oncology 116 (3), 473-477, 2010 | 60 | 2010 |
| Second-line lenvatinib in patients with recurrent endometrial cancer I Vergote, MA Powell, MG Teneriello, DS Miller, AA Garcia, ON Mikheeva, ... Gynecologic oncology 156 (3), 575-582, 2020 | 57 | 2020 |
| The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer … B Kotowicz, M Fuksiewicz, J Jonska-Gmyrek, M Bidzinski, M Kowalska Tumor Biology 37 (1), 1271-1278, 2016 | 53 | 2016 |
| A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. I Vergote, M Teneriello, MA Powell, DS Miller, AA Garcia, ON Mikheeva, ... Journal of Clinical Oncology 31 (15_suppl), 5520-5520, 2013 | 53 | 2013 |
| Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer I Ray‐Coquard, D Cibula, MR Mirza, A Reuss, C Ricci, N Colombo, ... International journal of cancer 146 (2), 439-448, 2020 | 47 | 2020 |
| Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours J Plisiecka-Hałasa, A Dansonka-Mieszkowska, A Rembiszewska, ... Annals of human genetics 66 (5-6), 353-359, 2002 | 42 | 2002 |
| Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter … C Fotopoulou, I Vergote, P Mainwaring, M Bidzinski, JB Vermorken, ... Annals of oncology 25 (1), 160-165, 2014 | 40 | 2014 |
| Comparison of the results of surgical treatment using laparoscopy and laparotomy in patients with endometrial cancer P Sobiczewski, M Bidzinski, P Derlatka, A Dańska-Bidzińska, J Gmyrek, ... International Journal of Gynecologic Cancer 15 (5), 2005 | 39 | 2005 |
| microRNAs in uterine sarcomas and mixed epithelial–mesenchymal uterine tumors: a preliminary report M Kowalewska, E Bakula-Zalewska, M Chechlinska, K Goryca, ... Tumor Biology 34, 2153-2160, 2013 | 37 | 2013 |
| The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients B Kotowicz, M Fuksiewicz, M Kowalska, J Jonska-Gmyrek, M Bidzinski, ... International Journal of Gynecologic Cancer 18 (6), 2008 | 35 | 2008 |
| Clinical significance of pretreatment serum levels of VEGF and its receptors, IL-8, and their prognostic value in type I and II endometrial cancer patients B Kotowicz, M Fuksiewicz, J Jonska-Gmyrek, A Berezowska, ... PLoS One 12 (10), e0184576, 2017 | 32 | 2017 |
| TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study J Kupryjanczyk, E Kraszewska, I Ziolkowska-Seta, R Madry, A Timorek, ... Bmc Cancer 8, 1-13, 2008 | 32 | 2008 |
